The latest biotech news

apheabio microorganism biopesticides biostimulants

News and Trends 26 Jun 2017

New Belgian Biotech will use Microorganisms to Replace Pesticides and Fertilizers

Aphea.Bio has gathered a total of €9M in funding to start working on a new technology to produce biopesticides and biostimulants for European agriculture. Belgium has a new biotech that will be dedicated to developing sustainable, microorganism-based biopesticides and biostimulants. Aphea.Bio has raised €7.7M in a Series A round led by the Belgian life sciences investor V-Bio Ventures in addition to a €1.3M grant […]

June 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

type 1 diabetes insulin therapy uppsala university hospital

News and Trends 23 Jun 2017

Diabetic Patients that Still Produce Insulin might be the Key to a New Therapy

A study from Uppsala University has identified higher levels of interleukin-35 in type 1 diabetics that still produce insulin years after their diagnosis. Researchers at Uppsala University have published the first study in humans that shows the potential of interleukin-35 (IL-35) as a promising new target to treat type 1 diabetes. The results, published in […]

June 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Jun 2017

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy

Noble Généthon has teamed up with ignominious Sarepta to develop a gene therapy for the Duchenne variety of the muscle wasting disease. Dedicated to rare diseases since 1990 and more recently to gene therapy, Généthon is one of very few not-for-profit companies in European biotech. Though it has not yet brought a drug to market, it is […]

June 22, 2017 - 3 minutesmins - By Evelyn Warner

Novartis Cardiovascular Canakinumab Phase III

News and Trends 22 Jun 2017

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III trial for cardiovascular disease. Novartis most recently boasted impressive Phase III results for its AMD drug, RTH258, that could yield the company a new blockbuster. Now, the Swiss drug maker announced that its cardiovascular drug, canakinumab, was able to meet its primary endpoint in […]

June 22, 2017 - 2 minutesmins - By Melanie De Almeida

Ose Immunotherapeutics bpifrance milestone bowel disease

News and Trends 22 Jun 2017

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease to the clinic, triggering a milestone payment from its partner Bpifrance. OSE Immunotherapeutics, based in Nantes, France, has received €2.6M from the French public investment agency Bpifrance after completing another milestone in the development of a therapy for inflammatory bowel disease. […]

June 22, 2017 - 1 minutemin - By Clara Rodríguez Fernández

cancer research uk grand challenge award

News and Trends 22 Jun 2017

What are the Biggest Cancer Challenges? The UK Offers £20M Prizes for Solutions!

Cancer Research UK is taking applications for £20M prizes from research groups worldwide that want to solve the biggest challenges in cancer research. Cancer Research UK is launching today its second round of the Grand Challenge to tear down some of the biggest barriers to the advancement of cancer therapy. The charity will shortlist the most promising […]

June 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Jun 2017

LAB282 Awards Second Funding Round to 5 Academic Projects at Oxford

Evotec and the University of Oxford have announced the academic projects that will receive a financial award to push them towards launching spin-outs. LAB282 is a partnership between the German biotech Evotec, Oxford University Innovation and Oxford Sciences Innovation, the University’s venture fund manager. Set up with the aim to bridge academia and industry in life sciences, LAB282 […]

June 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Cell Medica Catapult Therapy TCR Acquisition

News and Trends 21 Jun 2017

British Biotech Tops up its Cancer Pipeline with New TCR Therapy

Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all set to leverage its Dominant T cell receptor (TCR) platform technology, which the company licensed from University College London (UCL) last year, to enhance existing T cell […]

June 21, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 20 Jun 2017

Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer

Immunicum has reported new data on long-term follow-up of patients treated with ilixadencel, a unique dendritic cell therapy against cancer. Immunicum is a Swedish biotech developing a cell-based therapy against cancer. The company has just published in the Journal for Immunotherapy for Cancer detailed results from a Phase I/II trial evaluating its lead candidate ilixadencel. The cell […]

June 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […]

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 19 Jun 2017

This Company Uses the Human Microbiome to Discover New Disease Mechanisms

A whole new avenue to human health and disease could soon be accessible, thanks to the human tissue microbiome. Vaiomer has found a way to make it possible! Has anyone else ever been unsettled by the idea that the human body hosts about 10 times more microbes than human cells? Although this might seem an […]

June 19, 2017 - 5 minutesmins - By External Contributor

News and Trends 15 Jun 2017

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug. At the 2017 Annual European Congress of Rheumatology, currently being held in Madrid, Novartis has presented new data showing that Cosentyx (secukinumab) keeps improving symptoms of ankylosing spondylitis after three years of treatment and […]

June 15, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

New Belgian Biotech will use Microorganisms to Replace Pesticides and Fertilizers

Diabetic Patients that Still Produce Insulin might be the Key to a New Therapy

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

What are the Biggest Cancer Challenges? The UK Offers £20M Prizes for Solutions!

LAB282 Awards Second Funding Round to 5 Academic Projects at Oxford

British Biotech Tops up its Cancer Pipeline with New TCR Therapy

Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

This Company Uses the Human Microbiome to Discover New Disease Mechanisms

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!